But the experts in a follow-up vote unanimously endorsed offering boosters to people over the age of 65 and “individuals at high risk of severe Covid-19,”
- Officials from Pfizer made the case for boosters, arguing increasing “breakthrough infections” could lead to an uptick in cases of severe disease among vaccinated people, a trend experts from Israel told the committee they had noticed before introducing vaccine boosters.
- But many of the committee’s experts noted there is conflicting data on the need for shots for most people, and there isn’t yet evidence concretely showing the vaccine has become less effective at preventing severe disease and death from Covid-19.
- Deputy director of the FDA’s Office of Vaccines Research and Review, highlighted that much of the data presented to the agency was “not peer-reviewed and has not been reviewed by the FDA,” making it difficult to assess whether models were giving “the correct results.”
- Dr. Ofer Levy, an infectious disease specialist at Boston Children’s Hospital, said. “I just don’t think we’re there yet in terms of the data.”